SPRC שווי כולל של נכסי החברה SciSparc Ltd.

SciSparc Ltd (SPRC) is scaling its CNS therapy portfolio, aiming to attract investment by publishing test results. The business relies on Israeli centers where cannabinoid drugs for neurological disorders and Tourette syndrome are developed. Total assets amount to 11.81, while the historical price chart on GURU.Markets reflects geopolitical risks and the vulnerability of raw material supplies in biopharmaceuticals.

Total assets, reverse-calculated via ROA as the sum of equity and liabilities, measure the aggregate resources of SciSparc Ltd (SPRC), where the current value of 11.81 reflects the company's financial potential in competing with pharma behemoths for leadership in CNS therapy, while the trend of all assets allows investors to assess the base's resilience to high scientific risks and debt loads during the development of cannabinoid drugs.